185 related articles for article (PubMed ID: 35458417)
1. Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague.
Vagima Y; Gur D; Aftalion M; Moses S; Levy Y; Makovitzki A; Holtzman T; Oren Z; Segula Y; Fatelevich E; Tidhar A; Zauberman A; Rotem S; Mamroud E; Steinberger-Levy I
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458417
[TBL] [Abstract][Full Text] [Related]
2. Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.
Zauberman A; Gur D; Levy Y; Aftalion M; Vagima Y; Tidhar A; Chitlaru T; Mamroud E
J Infect Dis; 2019 Aug; 220(7):1147-1151. PubMed ID: 31095689
[TBL] [Abstract][Full Text] [Related]
3. Characterization of
Moses S; Vagima Y; Tidhar A; Aftalion M; Mamroud E; Rotem S; Steinberger-Levy I
Viruses; 2021 Jan; 13(1):. PubMed ID: 33440682
[TBL] [Abstract][Full Text] [Related]
4. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
Rosenzweig JA; Brackman SM; Kirtley ML; Sha J; Erova TE; Yeager LA; Peterson JW; Xu ZQ; Chopra AK
Antimicrob Agents Chemother; 2011 Nov; 55(11):5034-42. PubMed ID: 21859946
[TBL] [Abstract][Full Text] [Related]
5. Activation of Heme Oxygenase Expression by Cobalt Protoporphyrin Treatment Prevents Pneumonic Plague Caused by Inhalation of
Willix JL; Stockton JL; Olson RM; Anderson PE; Anderson DM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015027
[TBL] [Abstract][Full Text] [Related]
6. Transmission of Antimicrobial Resistant Yersinia pestis During a Pneumonic Plague Outbreak.
Andrianaivoarimanana V; Wagner DM; Birdsell DN; Nikolay B; Rakotoarimanana F; Randriantseheno LN; Vogler AJ; Sahl JW; Hall CM; Somprasong N; Cauchemez S; Schweizer HP; Razafimandimby H; Rogier C; Rajerison M
Clin Infect Dis; 2022 Mar; 74(4):695-702. PubMed ID: 34244722
[TBL] [Abstract][Full Text] [Related]
7. Bacteriophage-resistant mutants in Yersinia pestis: identification of phage receptors and attenuation for mice.
Filippov AA; Sergueev KV; He Y; Huang XZ; Gnade BT; Mueller AJ; Fernandez-Prada CM; Nikolich MP
PLoS One; 2011; 6(9):e25486. PubMed ID: 21980477
[TBL] [Abstract][Full Text] [Related]
8. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
[TBL] [Abstract][Full Text] [Related]
9. Treatment with Fluticasone Propionate Increases Antibiotic Efficacy during Treatment of Late-Stage Primary Pneumonic Plague.
Crane SD; Banerjee SK; Pechous RD
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0127521. PubMed ID: 34780267
[TBL] [Abstract][Full Text] [Related]
10. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
[No Abstract] [Full Text] [Related]
11. Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague.
Jakielaszek C; Hossain M; Qian L; Fishman C; Widdowson K; Hilliard JJ; Mannino F; Raychaudhuri A; Carniel E; Demons S; Heine HS; Hershfield J; Russo R; Mega WM; Revelli D; O'Dwyer K
Sci Transl Med; 2022 Jun; 14(647):eabg1787. PubMed ID: 35648812
[TBL] [Abstract][Full Text] [Related]
12. Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.
Xiao X; Zhu Z; Dankmeyer JL; Wormald MM; Fast RL; Worsham PL; Cote CK; Amemiya K; Dimitrov DS
PLoS One; 2010 Oct; 5(10):e13047. PubMed ID: 20976274
[TBL] [Abstract][Full Text] [Related]
13. Interplays of mutations in
Xiao L; Qi Z; Song K; Lv R; Chen R; Zhao H; Wu H; Li C; Xin Y; Jin Y; Li X; Xu X; Tan Y; Du Z; Cui Y; Zhang X; Yang R; Zhao X; Song Y
Front Cell Infect Microbiol; 2023; 13():1174510. PubMed ID: 37305418
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic Therapy of Plague: A Review.
Sebbane F; Lemaître N
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065940
[TBL] [Abstract][Full Text] [Related]
15. Bacterial filamentation of Yersinia pestis by beta-lactam antibiotics in experimentally infected mice.
Davis KJ; Vogel P; Fritz DL; Steele KE; Pitt ML; Welkos SL; Friedlander AM; Byrne WR
Arch Pathol Lab Med; 1997 Aug; 121(8):865-8. PubMed ID: 9278616
[TBL] [Abstract][Full Text] [Related]
16. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.
Sha J; Agar SL; Baze WB; Olano JP; Fadl AA; Erova TE; Wang S; Foltz SM; Suarez G; Motin VL; Chauhan S; Klimpel GR; Peterson JW; Chopra AK
Infect Immun; 2008 Apr; 76(4):1390-409. PubMed ID: 18227160
[TBL] [Abstract][Full Text] [Related]
17. Treatment of plague: promising alternatives to antibiotics.
Anisimov AP; Amoako KK
J Med Microbiol; 2006 Nov; 55(Pt 11):1461-1475. PubMed ID: 17030904
[TBL] [Abstract][Full Text] [Related]
18. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic treatment of experimental pneumonic plague in mice.
Byrne WR; Welkos SL; Pitt ML; Davis KJ; Brueckner RP; Ezzell JW; Nelson GO; Vaccaro JR; Battersby LC; Friedlander AM
Antimicrob Agents Chemother; 1998 Mar; 42(3):675-81. PubMed ID: 9517950
[TBL] [Abstract][Full Text] [Related]
20. Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection.
D'Arco C; McCormick AA; Arnaboldi PM
Vaccine; 2021 Mar; 39(9):1435-1444. PubMed ID: 33531196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
